InspireMD (NSPR) Q2 2026 earnings review
U.S. Recall Erases Momentum; Survival Mode Engaged
InspireMD’s high-flying U.S. growth story hit a brick wall in Q2. Following the voluntary recall of its CGuard Prime 135 cm delivery system, U.S. revenue went negative (-$351k) due to $734k in customer credits, dragging total revenue down 0.4% YoY. This is a brutal reversal from the 122% YoY growth posted just one quarter ago. While the international segment proved resilient, growing 21%, the underlying financial strain is severe. With a $14.3M net loss and cash balances halving over the last six months, management hit the emergency brake, announcing a $9M annualized cost-cutting program. The company's future now hinges entirely on securing near-term FDA approvals to re-enter the U.S. market before the cash runway evaporates.
🐂 Bull Case
Despite the U.S. pause, international revenue grew 21% to $2.1M, proving that demand for the core CGuard stent remains strong where the legacy delivery system is available.
Management anticipates FDA decisions on both the legacy CGuard platform and the CGuard Prime 80 cm TCAR system later this year, potentially unlocking the U.S. market shortly.
🐻 Bear Case
U.S. revenue went negative in Q2. A U.S. relaunch carries immense execution risk, as hospital Value Analysis Committees (VACs) may be hesitant to quickly re-adopt a recalled system.
Cash dropped by $11.2M this quarter to $30.4M. Even with $9M in planned annualized savings, the company is operating on a tight timeline that leaves zero room for FDA delays.
⚖️ Verdict: 🔴🔴
Highly Bearish. The U.S. recall didn't just pause growth; it shattered the balance sheet. Until the FDA greenlights a U.S. return, the company is fighting a ticking clock against its cash burn.
Key Themes
U.S. Revenue Growth is Reversing Dramatically
The financial impact of the CGuard Prime 135 cm recall materialized brutally in Q2. U.S. revenue was negative $351k, driven by $734k in customer credits. This breaks a streak of accelerating U.S. adoption that had reached $1.2M in Q1. The U.S. market was supposed to be the primary engine for margin expansion and volume growth; instead, it is currently a financial anchor.
Cash Burn Outpacing Recovery Timeline
Management claims the recall is a 'temporary and correctable' issue, but the balance sheet tells a more urgent story. Cash and equivalents plummeted from $54.2M at the end of 2025 to $30.4M at the end of Q2 2026. With a quarterly net loss of $14.3M, the company is burning cash too quickly to endure a prolonged FDA review process.
Emergency Cost Restructuring
To address the liquidity crisis, management initiated post-quarter savings actions designed to generate ~$9M in annual savings. This restructuring involves streamlining the commercial organization. While necessary for survival, cutting the U.S. commercial team directly contradicts the narrative of being ready to instantly capture market share once FDA approval is secured.
International Demand Remains Stable
The one bright spot is the international segment, which utilizes the legacy delivery system unaffected by the recall. International revenue grew 21% YoY to $2.12M. This steady performance validates management's claim that the core MicroNet stent technology is fundamentally sound and well-regarded by physicians, even if the new U.S. delivery system failed.
TCAR Pipeline Progresses (SwitchGuard)
Technology innovation continues despite the commercial pause. The company announced 100% acute device success in its CGUARDIANS II clinical trial (CGuard Prime 80 cm in TCAR procedures) with zero deaths or strokes at 30 days. Furthermore, patient enrollment has commenced for the CGUARDIANS III pivotal trial for the next-generation SwitchGuard neuroprotection system. TCAR represents a massive addressable market if they can survive long enough to commercialize it.
Gross Margins Crushed by Inventory and Credits
Gross margin is reversing sharply into negative territory. Q2 posted a gross loss of $774k. Even when adjusting out $612k in inventory impairments and $734k in revenue credits (Non-GAAP), the adjusted gross profit was only $572k (32% adjusted margin). Without the high-margin U.S. sales mix, InspireMD cannot reach the profitability profile of a standard medical device company.
Other KPIs
Decelerating profitability. The net loss widened from -$13.1M in the prior year and -$13.7M sequentially in Q1. Operating expenses actually rose 2.5% YoY to $13.67M, indicating that the company had not yet curbed spending during the quarter to offset the sudden drop in U.S. sales.
Stable YoY, but dangerously high relative to revenue. The $339k YoY increase was driven by U.S. commercial headcount and clinical trial expenses for SwitchGuard and CGuard Prime 80cm, offsetting lower G&A costs. The newly announced $9M annualized cost-cutting plan will primarily target these commercial expenses in Q3.
Guidance
Management executed a restructuring plan in Q3 designed to reduce the cost structure and streamline the commercial organization. This equates to roughly $2.25M in quarterly OpEx relief going forward, which is critical for extending the cash runway.
The entire U.S. recovery relies on these two submissions. The company expects decisions before the end of 2026. If approved, the U.S. commercial pause will end, acting as an immediate catalyst for growth.
Design changes to fix the recalled delivery system are currently undergoing validation testing. The timeline for actual clearance and market re-entry remains highly uncertain, posing significant long-term execution risk.
Key Questions
Cash Runway Viability
With $30.4M in cash and a Q2 net loss of $14.3M, how many quarters of runway does the $9M annualized cost-saving plan actually buy you? Are you exploring alternative financing options if the FDA review is delayed?
U.S. Commercial Restart Capabilities
You noted a streamlining of the commercial organization to align with 'near-term priorities.' Once FDA approval is achieved, will you have sufficient sales infrastructure left to effectively execute a rapid U.S. relaunch?
Physician Goodwill and VAC Friction
How many of the previously approved U.S. hospital Value Analysis Committees (VACs) have revoked their approvals due to the recall? Do you anticipate having to restart the 3-6 month VAC process from scratch for the remediated 135 cm system?